MLN2201

MLN2201 is a humanized monoclonal antibody inhibitor, targeting Integrin β2. MLN2201 inhibits the reperfusion injury after stroke and can be used for inflammatory diseases like ischemic stroke research[1][2].

Product Specifications

Product Name Alternative

YFC51.1; LDP-01

UNSPSC

12352203

Target

Integrin

Related Pathways

Cytoskeleton

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

References & Citations

[1]Legos JJ, et al. Pharmacological interventions for stroke: failures and future. Expert Opin Investig Drugs. 2002 May;11 (5) :603-14. |[2]Legos JJ, et al. Update on pharmacological strategies for stroke: prevention, acute intervention and regeneration. Curr Opin Investig Drugs. 2003 Jul;4 (7) :847-58.